ClinicalTrials.gg
CompletedNCT00666965Updated Apr 25, 2014Results posted

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

A Phase 2 interventional study of SPM 962 in Idiopathic Restless Legs Syndrome, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-04-25.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
7th of 19
230 · median 130
Started
2008
with 1 other
Phase 2
6 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
3 of 19
Otsuka Pharmaceutical Co., Ltd.

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 8th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

The primary objective of this study is to investigate efficacy and safety of SPM 962 in Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group comparative study following once-daily multiple transdermal doses of SPM 962 within a range of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.

03

Conditions studied

  • Idiopathic Restless Legs Syndrome

Keywords

  • SPM 962
  • rotigotine
  • Idiopathic Restless Legs Syndrome
  • RLS
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 20 and more and less than 80 years of age and is able to think about her/his participation at the time of .
  2. Subject meets the diagnosis of idiopathic RLS based on the 4 cardinal clinical features according to the IRLSSG/NIH.
  3. The following subject will be included in the study

    • Subject is not currently receiving treatment for RLS.
    • Subject has previously received treatment of either L-dopa or dopamine agonists and efficacy was observed in either of drugs.
  4. At baseline, subject has a score of ≧ 15 on the IRLS sum score and RLS symptoms occur twice and more a week (≧score 2 in IRLS Question 7)
  5. Subject has a score of ≧ 4 on the CGI Severity score at baseline

Exclusion criteria

Exclusion Criteria:

  1. Subject has secondary RLS in association with renal impairment such as uremia,iron deficiency anemia, and drug associated symptoms.
  2. Subject has, is suspected of having or has a history of sleep disorders such as sleep apnea syndrome, narcolepsy, sleep attacks/sudden onset of sleep.
  3. Subject has additional concomitant diseases or symptoms such as polyneuropathy (including diabetic neuropathy), akathisia,claudication varicoses,muscle fasciculation,painful legs moving toes and radiculopathy.
  4. Subject has other central nervous diseases like Parkinson's disease, dimentia, progressive supranuclear paresis, multisystem atrophy, Huntington's Chorea, amyotrophic lateral sclerosis, or Alzheimer's disease.
  5. At screening or baseline, subject has psychiatric condition like confusion, hallucination, delusion, excitation, deliria, abnormal behaviour.
  6. Subject has orthostatic hypotension or systolic BP marks ≦ 100 mm Hg and with a decrease of BP from supine to standing position of ≧ 30 mm Hg.
  7. Subject has a history of epilepsy, convulsion etc.
  8. Subject has serious cardiac dysfunction and/or arrhythmias (e.g., congestive heart failure Class III or IV by , myocardial infarction, angina pectoris, conduction system dysregulations, second or third degree AV block, complete left bundle branch block, sick-sinus-syndrome, ventricular fibrillation within twelve months prior to enrollment).
  9. Subject has arrhythmia and receiving Class Ia antiarrhythmic drugs(e.g., quinidine, procainamide), Class III antiarrhythmic drugs (e.g., amiodarone, sotalol)
  10. At screening and baseline, subject develops serious abnormality. Subjects has -interval >450 msec twice at screening. Subject has a the average QTc-interval from two ECGs >450 msec in males and >470 msec in females at baseline.
  11. Subject has long QT syndrome congenital.
  12. Subject has a serum potassium level \< 3.5 mEq/L at screening.
  13. Subject has a total ≧3.0 mg/dL or (GOT) and/or ALT(GPT) greater than 2.5 times the upper limit of the reference range (or ≧100 IU/L) at screening.
  14. Subject has BUN ≧ 30 mg/dL or serum creatinine ≧2.0 mg/dl at screening.
  15. Subject has a history of allergic reaction to topical agents such as transdermal patch.
  16. Subject is pregnant or nursing or woman who plans pregnancy during the trial.
  17. Subject pursues shift work or is subject to other continuous non-disease-related life conditions which do not allow regular sleep at night.
  18. Subject has disease, chronic active hepatitis or immune deficiency disorder.
  19. Subject has a malignant neoplastic disease requiring therapy within twelve months prior to screening.
  1. Subject received an drug from other clinical trial within the last 12 months prior to baseline.
  1. Subject is judged to be inappropriate for this trial by investigator on the other than above.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (actual)

Study arms

  • Placebo comparator
    1

    inactive placebo

    Drug: SPM 962

  • Experimental
    2

    2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets

    Drug: SPM 962

  • Experimental
    3

    4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet

    Drug: SPM 962

  • Experimental
    4

    6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets

    Drug: SPM 962

Interventions

  • transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks

    Also known as: rotigotine

06

What researchers measure

Primary outcomes

  1. Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period

    IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.

    Time frame: Baseline, end of maintenance period at 6 weeks

Secondary outcomes

  1. Clinical Global Impression (CGI) Severity

    CGI is a clinician-reported scale for assessing severity of illness. The sale scoring criteria are 1: Normal, not at all ill, 2: Borderline ill, 3: Mildly ill, 4: Moderately ill, 5: Markedly ill, 6: Severely ill, 7: Among the most extremely ill patients.

    Time frame: Baseline, 2 weeks, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.

  2. Patient Global Impression (PGI) Improvement

    The PGI-I is a self-rated 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Moderate and marked improvement = score of 1 or 2, Without improvement = score of 4, Marked and moderate aggravation = score of 6 or 7.

    Time frame: Baseline, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.

  3. The Pittsburgh Sleep Quality Index (PSQI)

    PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement. The data at 6 weeks after dosing is shown.

    Time frame: Baseline, every two weeks

  4. Medical Outcome Study (MOS) Short-Form 36-Item Health Survey (SF-36)

    Mean Change from baseline in MOS Short Form SF-36 to 6 weeks after dosing. SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.

    Time frame: Baseline, every two weeks

  5. IRLS Each Parameter

    IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement. The percentage of subjects with -3 or -4 changes from baseline in each parameter at 6 weeks after dosing is shown.

    Time frame: Baseline, every two weeks

07

Results

Posted Apr 25, 2014

Participant flow

Participant flow — Overall Study
MilestonePlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
Started58575857
Completed55535642
Not completed34215
Withdrew: Adverse event0219
Withdrew: Lack of efficacy1100
Withdrew: Protocol violation0002
Withdrew: Discontinuation criteria2112
Withdrew: Withdrawal by subject0002

Outcome measures

PrimaryChange of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period

IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.

Time frame:
Baseline, end of maintenance period at 6 weeks
Reported as:
Mean · scores on a scale
Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period
scores on a scalePlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period-9.8 ± 7.2-10.7 ± 6.3-14.4 ± 7.2-14.1 ± 8.8
SecondaryClinical Global Impression (CGI) Severity

CGI is a clinician-reported scale for assessing severity of illness. The sale scoring criteria are 1: Normal, not at all ill, 2: Borderline ill, 3: Mildly ill, 4: Moderately ill, 5: Markedly ill, 6: Severely ill, 7: Among the most extremely ill patients.

Time frame:
Baseline, 2 weeks, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.
Reported as:
Number · Percentage of Participants
Clinical Global Impression (CGI) Severity
Percentage of ParticipantsPlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
Decreased73.783.692.986.3
Increased1.81.80.03.9
Decreased to 1 or 212.318.241.139.2
Subjects with CGI score 58.812.73.67.8
Subjects without improvement26.316.47.113.7
4 at baseline and stayed at 426.513.310.710.7
5 at baseline and decreased to 1 or 2024.046.430.4
SecondaryPatient Global Impression (PGI) Improvement

The PGI-I is a self-rated 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Moderate and marked improvement = score of 1 or 2, Without improvement = score of 4, Marked and moderate aggravation = score of 6 or 7.

Time frame:
Baseline, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.
Reported as:
Number · Percentage of Participants
Patient Global Impression (PGI) Improvement
Percentage of ParticipantsPlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
Moderate and marked improvement55.470.482.185.4
Without improvement17.93.73.66.3
Moderate and marked aggravation0.00.01.80.0
SecondaryThe Pittsburgh Sleep Quality Index (PSQI)

PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement. The data at 6 weeks after dosing is shown.

Time frame:
Baseline, every two weeks
Reported as:
Number · Percentage of Participants
The Pittsburgh Sleep Quality Index (PSQI)
Percentage of ParticipantsPlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
Subjects with ≥60% decrease7.116.723.223.4
Subjects with ≥50% decrease25.027.839.344.7
SecondaryMedical Outcome Study (MOS) Short-Form 36-Item Health Survey (SF-36)

Mean Change from baseline in MOS Short Form SF-36 to 6 weeks after dosing. SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.

Time frame:
Baseline, every two weeks
Reported as:
Mean · Scores on a scale
Medical Outcome Study (MOS) Short-Form 36-Item Health Survey (SF-36)
Scores on a scalePlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
Physical functioning1.1 ± 8.11.6 ± 9.62.8 ± 12.70.1 ± 6.1
Role physical-0.4 ± 18.01.7 ± 18.71.3 ± 15.80.9 ± 11.9
Bodily pain-1.7 ± 25.05.0 ± 28.01.7 ± 27.412.6 ± 19.7
General health3.4 ± 16.42.5 ± 10.54.6 ± 14.84.9 ± 12.9
Vitality6.3 ± 16.66.5 ± 17.23.6 ± 19.96.5 ± 18.6
Social functioning-0.2 ± 19.34.4 ± 17.01.1 ± 18.44.0 ± 12.5
Role emotional-0.1 ± 18.45.7 ± 18.44.2 ± 18.70.7 ± 16.6
SecondaryIRLS Each Parameter

IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement. The percentage of subjects with -3 or -4 changes from baseline in each parameter at 6 weeks after dosing is shown.

Time frame:
Baseline, every two weeks
Reported as:
Number · Percentage of Participants
IRLS Each Parameter
Percentage of ParticipantsPlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
-4 (RLS discomfort)0.00.00.03.9
-3 (RLS discomfort)7.01.816.119.6
-4 (need to move around due to RLS symptoms)0.00.03.62.0
-3 (need to move around due to RLS symptoms)10.59.116.125.5
-4 (discomfort relief by moving around)0.00.01.82.0
-3 (discomfort relief by moving around)7.09.126.813.7
-4 (severity of RLS as a whole)0.00.00.02.0
-3 (severity of RLS as a whole)1.83.612.519.6
-4 (RLS symptoms frequency)1.83.63.69.8
-3 (RLS symptoms frequency)7.07.326.819.6
-4 (average duration of RLS symptoms)0.00.00.00.0
-3 (average duration of RLS symptoms)3.50.07.17.8
-4 (severity of sleep disturbance)0.00.01.82.0
-3 (severity of sleep disturbance)3.512.712.521.6
-4 (tiredness or sleepiness during the day)0.00.00.00.0
-3 (tiredness or sleepiness during the day)1.87.35.411.8
-4 (severity of impact on daily affaires)0.01.81.82.0
-3 (severity of impact on daily affaires)5.33.63.67.8
-4 (severity of mood disturbance)0.00.01.80.0
-3 (severity of mood disturbance)5.35.51.87.8

Adverse events

Collected over 7 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/58 (0%)29/58 (50%)
2.25 mg/Day—0/57 (0%)37/57 (64.9%)
4.5 mg/Day—0/58 (0%)50/58 (86.2%)
6.75 mg/Day—0/57 (0%)44/57 (77.2%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo2.25 mg/Day4.5 mg/Day6.75 mg/Day
NauseaGastrointestinal disorders8/5819/5725/5827/57
NasopharyngitisInfections and infestations14/5812/5715/5814/57
SomnolencePsychiatric disorders3/586/5711/5812/57
VomitingGastrointestinal disorders1/584/576/5811/57
Application Site PruritusGeneral disorders2/588/5711/5810/57
HeadacheNervous system disorders1/583/5711/585/57
Application Site ReactionGeneral disorders5/586/578/587/57
Application Site ErythemaGeneral disorders4/584/577/587/57
MalaiseGeneral disorders2/582/572/584/57
AnorexiaMetabolism and nutrition disorders0/581/571/584/57

Baseline characteristics

3 subjects (1 for each placebo, 4.5 mg/day and 6.75 mg/day arm) were excluded by criteria

Age, Categorical
Age, Categorical(Participants)Placebo2.25 mg/Day4.5 mg/Day6.75 mg/DayTotal
<=18 years00000
Between 18 and 65 years48484948193
>=65 years998834
Age, Continuous
Age, Continuous(years)Placebo2.25 mg/Day4.5 mg/Day6.75 mg/DayTotal
Mean48.6 ± 13.150.6 ± 13.048.3 ± 14.151.0 ± 12.449.6 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2.25 mg/Day4.5 mg/Day6.75 mg/DayTotal
Female37413332143
Male2016242484
Region of Enrollment
Region of Enrollment(participants)Placebo2.25 mg/Day4.5 mg/Day6.75 mg/DayTotal
Japan57575756227
08

Study locations

8 sites
  • Chubu region, Japan
  • Chugoku region, Japan
  • Hokkaido region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Kyushu region, Japan
  • Shikoku region, Japan
  • Tohoku region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2008
First posted
Apr 25, 2008
Start
Jun 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Apr 25, 2014
Last update
Apr 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00666965
Responsible party
Sponsor
First posted
Apr 25, 2008
Start date
Jun 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Apr 25, 2014
Last update
Apr 25, 2014

Study contacts

Katsuhisa Saito
study director · New Product Evaluation Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion